Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
- None.
- None.
Insights
The recent approval of Zokinvy in Japan marks a significant milestone for Eiger BioPharmaceuticals and its partner AnGes. The clinical trial data indicating a 72% reduction in the risk of death and an extension of life expectancy by 4.3 years is a profound advancement for patients with Hutchinson-Gilford progeria syndrome (HGPS). From a research perspective, the statistical significance (p<0.0001) of these results underscores the efficacy of Zokinvy as a disease-modifying agent, targeting the root cause of this genetic condition.
Considering the rarity and severity of HGPS, the development of effective treatments is both a medical and ethical imperative. The extended life expectancy could translate into improved quality of life and reduced healthcare costs associated with the management of progeria-related complications. This approval could also pave the way for further research into treatments for similar rare metabolic diseases, potentially opening new markets and therapeutic areas for Eiger BioPharmaceuticals.
The approval and subsequent $500,000 milestone payment from AnGes to Eiger BioPharmaceuticals are important financial events for the company. While the payment itself may be modest relative to the overall financials of a biopharmaceutical firm, it signifies the successful progression of Zokinvy in the global market. The approval in Japan, following the U.S. and European approvals, expands the drug's market reach, which is crucial for rare disease treatments that rely on smaller patient populations.
Investors should note that the market for ultra-rare diseases, while limited in size, often allows for premium pricing due to the lack of available treatments. The financial impact of Zokinvy's approval could therefore be significant for Eiger BioPharmaceuticals in the long term, especially if the drug maintains exclusivity and demonstrates continued clinical success.
The regulatory approval in Japan represents a key development in the global healthcare landscape, particularly for ultra-rare conditions like HGPS. The support of the Progeria Research Foundation highlights the collaborative nature of drug development for rare diseases, involving advocacy groups, patients and families. This collaborative model can expedite the regulatory process and ensure that patient needs are at the forefront of decision-making.
From a policy standpoint, the approval of Zokinvy sets a precedent for the treatment of rare pediatric diseases and may influence healthcare policy decisions regarding drug approval processes, access to treatments and insurance coverage. It also reflects the increasing global commitment to addressing the needs of patients with rare diseases, which is a positive trend for public health.
- Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeria
- Eiger to receive
$500,000 - Zokinvy approved in the
U.S. (2020), 30 European countries (2022), and nowJapan (2024)
"We and our partner, AnGes, are pleased that Zokinvy is now approved in
Collectively known as progeria, HGPS and PL are devastating ultra-rare and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The main cause of death is heart attack or stroke due to severe hardening of the arteries.3,4
The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by
About Progeria
Collectively known as progeria, Hutchinson-Gilford progeria syndrome and progeroid laminopathies are ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients.
HGPS is caused by a point mutation in the LMNA gene, yielding the farnesylated aberrant protein, progerin. Progeroid laminopathies are genetic conditions of accelerated aging caused by a constellation of mutations in the LMNA and/or ZMPSTE24 genes yielding farnesylated proteins that are distinct from progerin.4,5
Without Zokinvy therapy, children with HGPS commonly die of the same heart disease that affects millions of normally aging adults (arteriosclerosis), by an average age of 14.5 years. Disease manifestations include severe failure to thrive, scleroderma–like skin, global lipodystrophy, alopecia, joint contractures, skeletal dysplasia, global accelerated atherosclerosis with cardiovascular decline, and debilitating strokes.3
About Zokinvy® (lonafarnib)
Zokinvy is a first-in-class disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins which leads to cellular instability and premature aging in children and young adults with progeria. Zokinvy has demonstrated a statistically significant survival benefit in children and young adults with HGPS.1,4
The most commonly reported adverse reactions were gastrointestinal (vomiting, diarrhea, nausea), and most were mild or moderate (Grade 1 or 2) in severity. Many progeria patients have received continuous Zokinvy therapy for more than 10 years.1,2
Zokinvy is FDA approved for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.
For Important Safety Information and prescribing information for Zokinvy in the
Eiger and AnGes entered into an exclusive distribution agreement for the treatment of HGPS and PDPL indications, Zokinvy (Lonafarnib), in
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, prospective products, preclinical and clinical pipelines, regulatory objectives, business strategy and plans and objectives for future operations, are forward-looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the timing of our ongoing and planned clinical development; our capability to provide sufficient quantities of any of our products or product candidates for studies or to meet anticipated full-scale commercial demands; our ability to identify, pursue and enter into partnering opportunities for our virology assets; the sufficiency of our cash, cash equivalents and investments to fund our operations into the fourth quarter of 2024, including the scope and impact of any savings from our workforce reduction and cash conservation efforts; the revenue potential of avexitide in post-bariatric hypoglycemia and congenital hyperinsulinism; our ability to finance, independently or through collaborations, the continued advancement of our development pipeline; and the potential for success of any of our products or product candidates. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the "Risk Factors" section in Eiger's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
References:
1. Data on file, Eiger BioPharmaceuticals.
2. Summary of Product Characteristics, July 2022.
3. Gordon LB, Brown WT, Collins FS. Hutchinson-Gilford Progeria Syndrome. 2003 Dec 12
[Updated 2019 Jan 17]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of
4. Gordon LB, Shappell H, Massaro J, et al. Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome. JAMA. 2018;319(16):1687-1695. doi:10.1001/jama.2018.3264.
5. Marcelot A, Worman HJ, and Zinn-Justin S. Protein structural and mechanistic basis of progeroid laminopathies. FEBS Journal. 2021:288:2757-2772. Doi:10.111/febs.15526.
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-and-partner-anges-receive-approval-for-zokinvy-lonafarnib-for-hutchinson--gilford-progeria-syndrome-and-processing-deficient-progeroid-laminopathies-in-japan-302038919.html
SOURCE Eiger BioPharmaceuticals, Inc.
FAQ
What is the marketing approval received by Eiger BioPharmaceuticals, Inc. and AnGes, Inc. for Zokinvy?
What did the clinical trial data show about Zokinvy's effectiveness?
What are the main causes of death in patients with progeria?
